View Author
scopus: 35446926900

Jauch, K.W.

( K.W. Jauch)


patient group treatment hyperthermia study eia-alone group treatment group fracture therapy survival situation eia-alone chemotherapy surgery sarcoma analysis placebo hip fracture progression tumour resection response proportion baseline death change cycle journal event radiotherapy 75 years trial induction subject month phase european table result barthel index hospital cancer barthel index disease effect hgh group safety number hip fractures igf-i tissue induction therapy extremity centre follow-up hip fracture patients barthel index score pre-fracture growth oncol difference hormone germany placebo group outcome treatment groups period score progression-free survival non-extremity growth hormone bene fit therapy group endocrinology grade range tissue sarcomas 2 years randomised




2 Most Recent Publications

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study (Article)
Issels, R.D. Lindner, L.H. Vujaskovic, Z. Wessalowski, R. Jauch, K.W. Dürr, H.R. Ploner, F. Baur-Melnyk, A. Mansmann, U. Hiddemann, W. Blay, J-Y. Judson, I.R. Verweij, J. Wust, P. Reichardt, P. Schem, B.C. Abdel-Rahman, S. Daugaard, S. Salat, C. Wendtner, C.M.
2010-06-01
Use of human GH in elderly patients with accidental hip fracture (Article)
Lely, A.J. van der Lamberts, S.W.J. Jauch, K.W. Swierstra, B.A. Hertlein, H. Vries, D. de Birkett, M.A. Bates, P.C. Blum, W.F. Attanasio, A.F.
2000-01-01